[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621431":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":23,"interventions":35,"overallOfficials":13,"centralContacts":13,"locations":45,"responsibleParty":65,"collaborators":13,"id":69,"slug":13,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":13,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":13,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":13,"overallStatus":48,"whyStopped":13,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Tanta University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"- Change in The Unified Parkinson's Disease Rating Scale","\\- Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score","6 months",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"DOUBLE",[21,22],"PARTICIPANT","INVESTIGATOR",[24,30],{"label":25,"type":26,"description":27,"interventionNames":28},"Control group","ACTIVE_COMPARATOR","(levo-dopa group, n =30) who will receive levo-dopa\u002Fcarbidopa (125\u002F12.5) mg three times daily for 6 months.",[29],"Drug: L-dopa",{"label":31,"type":26,"description":32,"interventionNames":33},"Etoricoxib group","will receive levo-dopa\u002Fcarbidopa (125\u002F12.5) mg three times daily plus Etoricoxib 90 mg once daily",[29,34],"Drug: Etoricoxib",[36,41],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":13},"DRUG","L-dopa","Levodopa is the standard therapy in PD.",[25,31],{"type":37,"name":42,"description":43,"armGroupLabels":44,"otherNames":13},"Etoricoxib","Etoricoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1) and by the inducible COX-2 enzymes and are secreted mainly by astrocytes and microglia.",[31],[46],{"facility":47,"status":48,"city":49,"state":13,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Mansoura University","RECRUITING","Al Mansurah","26548","Egypt","EG",{"type":54,"coordinates":55},"Point",[56,57],31.38069,31.03637,{"lat":57,"lon":56},[60],{"name":61,"role":62,"phone":63,"phoneExt":13,"email":64},"Ehab Hassan, PhD","CONTACT","01067831661","Ehassan@horus.edu.eg",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"SPONSOR_INVESTIGATOR","Ihab Elsayed Hassan","Lecturer","100621431",false,"NCT07370532","Etoricoxib in Patients With Parkinsonian Disease","Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Both male and female will be included.\n* Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.\n\nExclusion Criteria:\n\n* Breast feeding\n* Patients with significant liver and kidney function abnormalities.\n* Alcohol and \u002F or drug abusers.\n* Patients with known allergy to the study medications\n* Pregnant women and women with planned pregnancy.\n* Patients who are currently using other anti-inflammatory drugs.","ALL","50 Years","70 Years",{"count":79,"type":80},60,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).",[86],"Parkinson Disease","2026-04-02",{"date":89,"type":90},"2026-04-08","ACTUAL",{"date":92,"type":90},"2026-01-30",{"date":94,"type":80},"2027-11-20",{"name":67,"class":6},1]